• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

RASSF1A通过抑制Yes相关蛋白1(YAP1)、抑制叉头框蛋白M1(FOXM1)以及激活叉头框转录因子3A(FOXO3A)来抑制雌激素依赖性乳腺癌细胞的生长。

RASSF1A Suppresses Estrogen-Dependent Breast Cancer Cell Growth through Inhibition of the Yes-Associated Protein 1 (YAP1), Inhibition of the Forkhead Box Protein M1 (FOXM1), and Activation of Forkhead Box Transcription Factor 3A (FOXO3A).

作者信息

Roßwag Sven, Thiede Gitta, Sleeman Jonathan P, Thaler Sonja

机构信息

European Center for Angioscience, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.

KIT Campus Nord, Institute for Toxicology and Genetics, 76344 Karlsruhe, Germany.

出版信息

Cancers (Basel). 2020 Sep 21;12(9):2689. doi: 10.3390/cancers12092689.

DOI:10.3390/cancers12092689
PMID:32967092
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7566002/
Abstract

The estrogen receptor alpha (ERα) is expressed by the majority of breast cancers and plays an important role in breast cancer development and tumor outgrowth. Although ERα is well known to be a specific and efficient therapeutic target, the molecular mechanisms that are responsible for the control of ERα expression and function in the context of breast cancer initiation and progression are complex and not completely elucidated. In previous work, we have demonstrated that the tumor suppressor RASSF1A inhibits ERα expression and function in ERα-positive breast cancer cells through an AKT-dependent mechanism. Transcriptional activators such as forkhead box protein M1 (FOXM1) and forkhead transcription factor 3A (FOXO3A) and signaling pathways such as the Hippo pathway are also known to modulate ERα expression and activity. Here we report that RASSF1A acts as an inhibitor of ERα-driven breast cancer cell growth through a complex, hierarchically organized network that initially involves suppression of the Hippo effector Yes-associated protein 1 (YAP1), which is followed by inhibition of AKT1 activity, increased FOXO3A activity as well as a blockade of FOXM1 and ERα expression. Together our findings provide important new mechanistic insights into how the loss of RASSF1A contributes to ERα+ breast cancer initiation and progression.

摘要

雌激素受体α(ERα)在大多数乳腺癌中表达,在乳腺癌发展和肿瘤生长中起重要作用。尽管众所周知ERα是一个特定且有效的治疗靶点,但在乳腺癌发生和进展过程中负责控制ERα表达和功能的分子机制复杂且尚未完全阐明。在先前的研究中,我们已经证明肿瘤抑制因子RASSF1A通过一种依赖AKT的机制抑制ERα阳性乳腺癌细胞中ERα的表达和功能。转录激活因子如叉头框蛋白M1(FOXM1)和叉头转录因子3A(FOXO3A)以及信号通路如Hippo通路也已知可调节ERα的表达和活性。在此我们报告,RASSF1A通过一个复杂的、层次组织化的网络作为ERα驱动的乳腺癌细胞生长的抑制剂,该网络最初涉及抑制Hippo效应器Yes相关蛋白1(YAP1),随后抑制AKT1活性、增加FOXO3A活性以及阻断FOXM1和ERα的表达。我们的研究结果共同为RASSF1A缺失如何促进ERα阳性乳腺癌的发生和进展提供了重要的新机制见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/63927e1b5aec/cancers-12-02689-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/c826a081e104/cancers-12-02689-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/17f2f9765144/cancers-12-02689-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/85d876a84297/cancers-12-02689-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/cc95e1f7024d/cancers-12-02689-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/2aa5e19cfbec/cancers-12-02689-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/e5c56b2af62a/cancers-12-02689-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/ec53cd254a85/cancers-12-02689-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/dea64f1fe177/cancers-12-02689-g008a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/63927e1b5aec/cancers-12-02689-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/c826a081e104/cancers-12-02689-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/17f2f9765144/cancers-12-02689-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/85d876a84297/cancers-12-02689-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/cc95e1f7024d/cancers-12-02689-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/2aa5e19cfbec/cancers-12-02689-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/e5c56b2af62a/cancers-12-02689-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/ec53cd254a85/cancers-12-02689-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/dea64f1fe177/cancers-12-02689-g008a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfd9/7566002/63927e1b5aec/cancers-12-02689-g009.jpg

相似文献

1
RASSF1A Suppresses Estrogen-Dependent Breast Cancer Cell Growth through Inhibition of the Yes-Associated Protein 1 (YAP1), Inhibition of the Forkhead Box Protein M1 (FOXM1), and Activation of Forkhead Box Transcription Factor 3A (FOXO3A).RASSF1A通过抑制Yes相关蛋白1(YAP1)、抑制叉头框蛋白M1(FOXM1)以及激活叉头框转录因子3A(FOXO3A)来抑制雌激素依赖性乳腺癌细胞的生长。
Cancers (Basel). 2020 Sep 21;12(9):2689. doi: 10.3390/cancers12092689.
2
RASSF1A-Mediated Suppression of Estrogen Receptor Alpha (ERα)-Driven Breast Cancer Cell Growth Depends on the Hippo-Kinases LATS1 and 2.RASSF1A 通过抑制 Hippo 激酶 LATS1 和 2 抑制雌激素受体 α(ERα)驱动的乳腺癌细胞生长。
Cells. 2021 Oct 24;10(11):2868. doi: 10.3390/cells10112868.
3
The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells.叉头框M1蛋白调节乳腺癌细胞中雌激素受体α的转录。
J Biol Chem. 2006 Sep 1;281(35):25167-76. doi: 10.1074/jbc.M603906200. Epub 2006 Jun 28.
4
Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway.叉头框转录因子FOXO3a调节雌激素受体α的表达,并受到Her-2/neu/磷脂酰肌醇3激酶/Akt信号通路的抑制。
Mol Cell Biol. 2004 Oct;24(19):8681-90. doi: 10.1128/MCB.24.19.8681-8690.2004.
5
Increased expression of forkhead box M1 is associated with aggressive phenotype and poor prognosis in estrogen receptor-positive breast cancer.叉头框蛋白M1表达增加与雌激素受体阳性乳腺癌的侵袭性表型及不良预后相关。
J Korean Med Sci. 2015 Apr;30(4):390-7. doi: 10.3346/jkms.2015.30.4.390. Epub 2015 Mar 19.
6
Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor alpha expression reversing invasive phenotype of breast cancer cells.绿茶多酚表没食子儿茶素-3-没食子酸酯对FOXO3a的激活可诱导雌激素受体α表达,逆转乳腺癌细胞的侵袭表型。
Cancer Res. 2007 Jun 15;67(12):5763-70. doi: 10.1158/0008-5472.CAN-06-4327.
7
FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.FOXO3a 通过 FOXM1 依赖性和非依赖性机制抑制乳腺癌中的 VEGF 表达。
Oncogene. 2012 Apr 5;31(14):1845-58. doi: 10.1038/onc.2011.368. Epub 2011 Aug 22.
8
Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER.G蛋白偶联雌激素受体GPER介导雌激素对FOXO3a的失活作用。
BMC Cancer. 2015 Oct 15;15:702. doi: 10.1186/s12885-015-1699-6.
9
AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.AKT3调节ErbB2、ErbB3和雌激素受体α的表达,并导致来自Balb-neuT小鼠的ErbB2(+)乳腺肿瘤细胞产生内分泌治疗耐药性。
Cell Signal. 2014 May;26(5):1021-9. doi: 10.1016/j.cellsig.2014.01.018. Epub 2014 Jan 24.
10
Transcription Regulation and Genome Rewiring Governing Sensitivity and Resistance to FOXM1 Inhibition in Breast Cancer.转录调控与基因组重排对乳腺癌中FOXM1抑制敏感性和抗性的调控
Cancers (Basel). 2021 Dec 14;13(24):6282. doi: 10.3390/cancers13246282.

引用本文的文献

1
FOXO3a-interacting proteins' involvement in cancer: a review.FOXO3a 相互作用蛋白在癌症中的作用:综述。
Mol Biol Rep. 2024 Jan 25;51(1):196. doi: 10.1007/s11033-023-09121-w.
2
RASSF1A-Mediated Suppression of Estrogen Receptor Alpha (ERα)-Driven Breast Cancer Cell Growth Depends on the Hippo-Kinases LATS1 and 2.RASSF1A 通过抑制 Hippo 激酶 LATS1 和 2 抑制雌激素受体 α(ERα)驱动的乳腺癌细胞生长。
Cells. 2021 Oct 24;10(11):2868. doi: 10.3390/cells10112868.
3
Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer.

本文引用的文献

1
The tumor suppressor RASSF1A induces the YAP1 target gene that is epigenetically inactivated in human cancers and inhibits tumor growth.肿瘤抑制因子RASSF1A可诱导YAP1靶基因,该基因在人类癌症中发生表观遗传失活并抑制肿瘤生长。
Oncotarget. 2017 May 23;8(51):88437-88452. doi: 10.18632/oncotarget.18177. eCollection 2017 Oct 24.
2
Hippo Signaling Suppresses Cell Ploidy and Tumorigenesis through Skp2.河马信号通路通过Skp2抑制细胞倍性和肿瘤发生。
Cancer Cell. 2017 May 8;31(5):669-684.e7. doi: 10.1016/j.ccell.2017.04.004.
3
PLK1 is a binding partner and a negative regulator of FOXO3 tumor suppressor.
将Hippo信号通路作为治疗内分泌抵抗性乳腺癌的靶点。
Cancer Cell Int. 2021 Jun 10;21(1):306. doi: 10.1186/s12935-021-01999-5.
PLK1是FOXO3肿瘤抑制因子的结合伴侣和负调节因子。
Discoveries (Craiova). 2014 Apr-Jun;2(2). doi: 10.15190/d.2014.8.
4
miR-34a induces cellular senescence via modulation of telomerase activity in human hepatocellular carcinoma by targeting FoxM1/c-Myc pathway.微小RNA-34a通过靶向FoxM1/c-Myc通路调节端粒酶活性,从而诱导人肝癌细胞衰老。
Oncotarget. 2015 Feb 28;6(6):3988-4004. doi: 10.18632/oncotarget.2905.
5
The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.蛋白酶体抑制剂硼替佐米(万珂)作为潜在的雌激素受体阳性乳腺癌抑制剂。
Int J Cancer. 2015 Aug 1;137(3):686-97. doi: 10.1002/ijc.29404. Epub 2015 Jan 8.
6
FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance.FOXM1:一种新出现的DNA损伤反应和基因毒性剂抗性的主要调节因子。
Biochim Biophys Acta. 2014 Nov;1839(11):1316-22. doi: 10.1016/j.bbagrm.2014.09.016. Epub 2014 Oct 5.
7
RASSF1A-LATS1 signalling stabilizes replication forks by restricting CDK2-mediated phosphorylation of BRCA2.RASSF1A-LATS1信号通路通过限制CDK2介导的BRCA2磷酸化来稳定复制叉。
Nat Cell Biol. 2014 Oct;16(10):962-71, 1-8. doi: 10.1038/ncb3035. Epub 2014 Sep 14.
8
FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance.叉头框蛋白M1(FOXM1)靶向NBS1以调控DNA损伤诱导的衰老和表柔比星耐药性。
Oncogene. 2014 Aug 7;33(32):4144-55. doi: 10.1038/onc.2013.457. Epub 2013 Oct 21.
9
Forkhead box proteins: tuning forks for transcriptional harmony.叉头框蛋白:转录和谐的调音叉。
Nat Rev Cancer. 2013 Jul;13(7):482-95. doi: 10.1038/nrc3539.
10
RASSF1A Promoter Methylation Levels Positively Correlate with Estrogen Receptor Expression in Breast Cancer Patients.乳腺癌患者中 RASSF1A 启动子甲基化水平与雌激素受体表达呈正相关。
Transl Oncol. 2013 Jun 1;6(3):297-304. doi: 10.1593/tlo.13244. Print 2013 Jun.